医学
心脏病学
狭窄
内科学
肾动脉狭窄
血运重建
肾血管性高血压
病变
药物治疗
随机对照试验
临床试验
肾动脉
肾动脉阻塞
血流动力学
血压
放射科
干预(咨询)
血管成形术
耐火材料(行星科学)
肾
外科
肺动脉
血管疾病
肾脏疾病
作者
Arend J. J. Woittiez,Cornelis T. Postma,Peter W. de Leeuw
标识
DOI:10.1016/j.xkme.2026.101406
摘要
Atherosclerotic renal artery stenosis (ARAS) remains a complex contributor to hypertension and kidney disease. Although randomized trials failed to show benefit of revascularization on top of medical therapy over medical therapy alone, mounting evidence suggests that earlier stages of ARAS may still be clinically relevant. In this review, we will reevaluate assumptions about the relationship between lesion severity and clinical outcomes and highlight the discrepancy between angiographic definitions of significant stenosis and functional renal impairment. We suggest that with all degrees of angiographically identified ARAS, particularly in patients with refractory hypertension, Kidney failure, or flash pulmonary edema, the hemodynamic importance of the stenosis should be estimated. In this regard, a pressure drop of 10% or more across the stenosis is an indication that hypertension may be related to the obstruction. Because the classical definition of a hemodynamically significant stenosis precludes earlier and potentially more adequate opportunities for intervention, it is presently unknown if patients with ARAS of less than 60% stenosis would benefit from mechanical treatment. We suggest reevaluating the thresholds for intervention and call for new trials focused on early-stage atherosclerotic renal vascular disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI